CACNA1A (Calcium Voltage-Gated Channel Subunit Alpha1 A) encodes the alpha-1A subunit of voltage-gated P/Q-type calcium channels (CaV2.1), one of the most important voltage-gated calcium channels in the central nervous system. These channels are critical for neurotransmitter release at presynaptic terminals, particularly in cerebellar Purkinje cells and hippocampal neurons. Mutations in CACNA1A cause a spectrum of neurological disorders including spinocerebellar ataxias, familial hemiplegic migraine, episodic ataxia, and epilepsy [1].
| CACNA1A Gene Information | |
|---|---|
| Symbol | CACNA1A |
| Full Name | Calcium Voltage-Gated Channel Subunit Alpha1 A |
| Chromosomal Location | 19p13.2 |
| NCBI Gene ID | [773](https://www.ncbi.nlm.nih.gov/gene/773) |
| OMIM | [601011](https://www.omim.org/entry/601011) |
| Ensembl ID | [ENSG00000141837](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000141837) |
| UniProt | [O00555](https://www.uniprot.org/uniprot/O00555) |
| Protein | [CaV2.1 (P/Q-type calcium channel)](/proteins/cav2.1-) |
| Associated Diseases | [SCA2](/diseases/spinocerebellar-ataxia-type-2), [FHM](/diseases/familial-hemiplegic-migraine), [Epilepsy](/diseases/epilepsy), [Developmental Ataxia](/diseases/developmental-ataxia) |
The CACNA1A gene is essential for normal neurological function. It encodes the pore-forming alpha-1A subunit of P/Q-type calcium channels, which are high-voltage-activated channels that conduct calcium ions essential for synaptic transmission. The channel consists of multiple subunits:
P/Q-type channels are the predominant calcium channel type at cerebellar synapses, where they mediate fast synaptic transmission and are critical for proper motor coordination [2].
CACNA1A-encoded CaV2.1 channels play several critical roles in the nervous system:
Synaptic Transmission: P/Q-type channels are the primary voltage-gated calcium channels at presynaptic terminals, triggering neurotransmitter release through their high-affinity calcium binding [3].
Cerebellar Function: CaV2.1 channels are essential for proper cerebellar Purkinje cell function, which integrates motor learning signals and coordinates movement.
Hippocampal Signaling: In the hippocampus, P/Q-type channels contribute to synaptic plasticity, learning, and memory processes.
Neuromuscular Junction: At the motor nerve terminal, P/Q-type channels mediate acetylcholine release for muscle contraction.
Gene Regulation: Through calcium-dependent signaling cascades, these channels regulate transcription factors and gene expression programs important for neuronal survival.
The CaV2.1 channel has complex gating properties:
CaV2.1 channels are expressed in a cell-type specific manner:
| Brain Region | Expression Level | Primary Cell Types |
|---|---|---|
| Cerebellum | Very High | Purkinje cells, Granule cells |
| Hippocampus | High | CA3 pyramidal cells, Interneurons |
| Cerebral Cortex | High | Layer 5 pyramidal neurons |
| Thalamus | High | Relay neurons |
| Dorsal Root Ganglia | Moderate | Sensory neurons |
| Brainstem | Moderate | Various neuron types |
The high expression in cerebellar Purkinje cells explains the ataxia phenotypes observed in CACNA1A mutations [4].
Emerging evidence links CACNA1A to Alzheimer's disease pathogenesis:
| AD Association | Mechanism |
|---|---|
| Calcium dysregulation | Altered channel expression/function |
| Synaptic impairment | Reduced neurotransmitter release |
| Excitotoxicity | Abnormal calcium influx |
| Memory deficits | Hippocampal dysfunction |
While less studied than in AD, CACNA1A may play roles in PD:
CACNA1A mutations cause SCA2, one of the most common autosomal dominant ataxias:
| Disorder | CACNA1A Role |
|---|---|
| Familial Hemiplegic Migraine (FHM) | Gain-of-function mutations cause aura and hemiparesis |
| Episodic Ataxia Type 2 (EA2) | Loss-of-function mutations cause episodic ataxia and nystagmus |
| Epilepsy | Various mutations cause neuronal hyperexcitability |
| Developmental Ataxia | Developmental delays with ataxic features |
| Approach | Status | Target |
|---|---|---|
| Gene therapy | Preclinical | Restore channel function |
| Small molecule correctors | Discovery | Improve channel trafficking |
| Antisense oligonucleotides | Research | Reduce toxic protein expression |
| Calcium channel blockers | Clinical trials | Reduce excitotoxicity |
Pietrobon D. "CaV2.1 channelopathies." Pflugers Archiv : European journal of physiology (2010). Pflugers Archiv : European journal of physiology. 2010. ↩︎
Graves TD et al. "The episodic ataxias." Handbook of clinical neurology (2024). Handbook of clinical neurology. 2024. ↩︎
Mintz IM et al. "P-type calcium channels in rat central and peripheral neurons." Neuron (1992). Neuron. 1992. ↩︎
Cunha P et al. "Extreme phenotypic heterogeneity in non-expansion spinocerebellar ataxias." American journal of human genetics (2023). American journal of human genetics. 2023. ↩︎
Du X et al. "Calcium channel dysfunction in the entorhinal cortex in Alzheimer disease." Neurobiology of Aging (2015). Neurobiology of Aging. 2015. ↩︎
Chen X et al. "P/Q-type calcium channel dysfunction in primary cortical neurons from the 5xFAD mouse model of Alzheimer disease." Acta Neuropathologica Communications (2020). Acta Neuropathologica Communications. 2020. ↩︎
Mori Y et al. "Primary structure and functional expression from complementary DNA of the brain calcium channel." Nature (1991). Nature. 1991. ↩︎
Ophoff RA et al. "Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4." Cell (1996). Cell. 1996. ↩︎
Hommersom MP et al. "CACNA1A haploinsufficiency leads to reduced synaptic function and increased intrinsic excitability." Brain : a journal of neurology (2025). Brain : a journal of neurology. 2025. ↩︎